Hepatitis C therapy update.
Curr Opin Gastroenterol
; 28(3): 188-92, 2012 May.
Article
in En
| MEDLINE
| ID: mdl-22476156
ABSTRACT
PURPOSE OF REVIEW We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. RECENT FINDINGS:
Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy.SUMMARY:
Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.
Full text:
1
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Oligopeptides
/
Proline
/
Hepatitis C, Chronic
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Curr Opin Gastroenterol
Journal subject:
GASTROENTEROLOGIA
Year:
2012
Type:
Article
Affiliation country:
United States